|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||15.41 - 15.69|
|52 Week Range||12.55 - 21.59|
|Beta (5Y Monthly)||1.23|
|PE Ratio (TTM)||8.51|
|Forward Dividend & Yield||0.76 (4.79%)|
|Ex-Dividend Date||Apr 29, 2020|
|1y Target Est||22.84|
Ken Feinberg, who is mediating talks, said his "optimism knows no bounds," and that he expected the next set of cases scheduled for trial to soon settle. U.S. District Judge Vince Chhabria in San Francisco kept a stay on litigation until Nov. 2 and asked the parties for a status update at that time. Bayer, which acquired Roundup with its purchase of Monsanto for $63 billion in 2018, agreed in June to pay around $11 billion to settle the lawsuits, which have pummeled the company's share price.
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Bayer AG and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Three of the cheapest stocks right now are an ad-tech company, a healthcare conglomerate, and a pharmacy giant. Let's take a look at why they are ideal choices for value investors. One of the cheapest stocks in the entire tech sector is French ad-tech company Criteo (NASDAQ: CRTO).